ABSTRACT
It is generally assumed that the neuropathology of sporadic (late-onset or nonfamilial) Alzheimer's disease (AD) is driven by the overproduction and spreading of first Amyloid-ßx-42 (Aß42) and later hyperphosphorylated (hp)-Tau oligomeric "infectious seeds". Hitherto, only neurons were held to make and spread both oligomer types; astrocytes would just remove debris. However, we have recently shown that exogenous fibrillar or soluble Aß peptides specifically bind and activate the Ca(2+)-sensing receptors (CaSRs) of untransformed human cortical adult astrocytes and postnatal neurons cultured in vitro driving them to produce, accrue, and secrete surplus endogenous Aß42. While the Aß-exposed neurons start dying, astrocytes survive and keep oversecreting Aß42, nitric oxide (NO), and vascular endothelial growth factor (VEGF)-A. Thus astrocytes help neurons' demise. Moreover, we have found that a highly selective allosteric CaSR agonist ("calcimimetic"), NPS R-568, mimics the just mentioned neurotoxic actions triggered by AßâCaSR signaling. Contrariwise, and most important, NPS 2143, a highly selective allosteric CaSR antagonist ("calcilytic"), fully suppresses all the AßâCaSR signaling-driven noxious actions. Altogether our findings suggest that the progression of AD neuropathology is promoted by unceasingly repeating cycles of accruing exogenous Aß42 oligomers interacting with the CaSRs of swelling numbers of astrocyte-neuron teams thereby recruiting them to overrelease additional Aß42 oligomers, VEGF-A, and NO. Calcilytics would beneficially break such Aß/CaSR-driven vicious cycles and hence halt or at least slow the otherwise unstoppable spreading of AD neuropathology.
ABSTRACT
In this work we have investigated the molecular basis of the neuronal damage induced by the prion peptide by searching for a surface receptor whose activation could be the first step of a cascade of events responsible for cell death. By using a human neuroblastoma cell line lacking all the neurotrophin receptors and derived clones expressing the full-length or truncated forms of the low affinity neurotrophin receptor (p75(NTR)), we have been able to demonstrate that the neuronal death induced by the prion protein fragment PrP-(106-126) is an active process mediated by a) the binding of the peptide to the extracellular region of p75(NTR), b) the signaling function of the intracytoplasmic region of the receptor, and c) the activation of caspase-8 and the production of oxidant species.
Subject(s)
Neurons/metabolism , Peptide Fragments/metabolism , Prions/metabolism , Receptors, Nerve Growth Factor/chemistry , Receptors, Nerve Growth Factor/metabolism , Binding Sites , Blotting, Northern , Blotting, Western , Caspase 8 , Caspase 9 , Caspases/metabolism , Dose-Response Relationship, Drug , Enzyme Activation , Enzyme Inhibitors/pharmacology , Humans , Microscopy, Fluorescence , Neuroblastoma/metabolism , Oxygen/metabolism , Protein Binding , Receptor, Nerve Growth Factor , Staurosporine/pharmacology , Time Factors , Tumor Cells, CulturedABSTRACT
A caspase-mediated release of the 40-kDa catalytic fragment of the delta isoform (CF-delta) of protein kinase C (PKC-delta) is involved in apoptosis, but its actual role in apoptosis development is still unknown. In an effort to understand this role, we have used polyomavirus-transformed pyF111 rat fibroblasts, which are hypersusceptible to apoptosis as they constitutively hyperexpress PKC-delta, but cannot make the antiapoptotic Bcl-2 and Bcl-X(L) proteins, while making the proapoptotic Bax protein. Calphostin C is reportedly both a specific inhibitor of PKC-delta activity (C. Keenan, N. Goode, and C. Pears, 1997, FEBS Lett. 415, 101-108) and an effective apoptogen (M. Murata et al., 1997, Cell. Mol. Life Sci. 53, 737-743). Exposure of pyF111 cells to calphostin C (75 nM) stimulated the translocation of the PKC-delta holoenzyme (holo-PKC-delta) onto the cytoplasmic particulate (CP) fraction between 15 and 45 min, which was after the release of mitochondrial cytochrome c but before the activation of cytoplasmic DEVD-specific caspases. The CF-delta fragment started accumulating only between 2 and 4 h, while apoptosis occurred mostly within 6 h. Incubating pyF111 cells with the much slower acting, apoptogenic topoisomerase-II inhibitors etoposide (VP-16) and teniposide (VM-26) also caused within 6 h a doubling of the CP-bound holo-PKC-delta-related activity but with no significant translocation of the holoenzyme to the CP fraction. Again this occurred after the release of cytochrome c but before the activation of DEVDases and the accumulation of the CF-delta. However, while calphostin C did not affect the delta-related activity in the nuclear membrane (NM) and nucleoplasmic (NP) fractions, VP-16 and VM-26 caused a prompt, large, and irreversible drop in the delta activity at the NM and a transient surge followed by a fall in the NP-associated activity. Hence, a surge of CP-anchored holo-PKC-delta activity is a common part of the signals given by various apoptogenic drugs to pyF111 cells. On the other hand, inhibition of delta-related activity, first at the NM and then in the NP fraction, is a specific feature only of the signals given by apoptogenic DNA-damaging agents.
Subject(s)
Caspases/metabolism , Enzyme Inhibitors/pharmacology , Fibroblasts/metabolism , Isoenzymes/metabolism , Naphthalenes/pharmacology , Protein Kinase C/metabolism , Animals , Cell Line, Transformed , Cytoplasm/metabolism , Cytoplasm/pathology , Enzyme Activation , Fibroblasts/pathology , Protein Kinase C-delta , Rats , Topoisomerase II InhibitorsABSTRACT
Protein kinase C-delta (PKC-delta) appears to be variously involved in proliferation and apoptosis. To compare the changes of this enzyme in these two processes, we have determined the levels and activities of the 79-kDa PKC-delta holoenzyme and its catalytically active 47- and 40-kDa C-terminal fragments in the nuclei of proliferating untreated polyomavirus-transformed pyF111 rat fibroblasts and pyF111 cells treated with the apoptogenic topoisomerase-II inhibitors VP-16 (etoposide), VM-26 (teniposide), and doxorubicin. PyF111 cells were chosen because they hyperexpress PKC-delta and they are hypersusceptible to apoptosis because they do not express the antiapoptotic proteins Bcl-2 and Bcl-XL. The highest PKC-delta activity in cells before they started proliferating or were exposed to one of the inhibitors was in the NM (nuclear envelope-containing) fraction, which contained the holoenzyme and both C-terminal fragments, while only the two fragments were in the nucleoplasmic (NP) fraction where they were tightly associated with chromatin. When the cells began proliferating the amounts of the PKC-delta holoenzyme and the two fragments increased in the NM and the NP fractions and the already high PKC-delta activity either increased or stayed the same in these fractions until the end of the 72-h incubation. And there was no leakage of cytochrome c from the mitochondria into the cytoplasm. VP-16 exposure caused a prompt release of cytochrome c from the mitochondria into the cytosol and at the same time triggered a sharp drop (35% by 3 h and 60% by 6 h) in the PKC-delta activity in the NM fraction without changing the actual amounts of the holoenzyme or its fragments. This prompt inactivation of PKC-delta and its fragments during the first 6 h of exposure to the drug was not due to their dephosphorylation and could not be reversed by phosphatidylserine and/or 12-O-tetradecanoylphorbol 13-acetate (TPA). Between 6 and 24 h the PKC-delta activity in the NM fraction dropped a further 20%, the kinase's activity transiently surged in the NP fraction, and cytoplasmic CPP-32-like (DEVD-specific caspase) activity increased without an increase in the proteolysis of nuclear PKC-delta or PARP. Between 24 and 72 h nuclear CPP-32-like activity increased along with a massive proteolysis of PKC-delta, an accumulation of various PKC-delta fragments, and the cleavage of PARP. But despite this proteolysis, the cells were still able to maintain or even increase the amounts of holoenzyme and 40- and 47-kDa fragments in the NM and NP fractions before dying. VM-26 and doxorubicin caused the same prompt release of cytochrome c from the mitochondria and dramatic drop of NM PKC-delta activity as did VP-16. Thus, high levels of activity of nuclear PKC-delta, particularly PKC-delta in the nuclear membrane, might have a role driving the cell cycle of pyF111 cells. On the other hand, the prompt and sustained large drop in the activity of PKC-delta at this site that precedes the onset of the caspase-mediated proteolysis of the isoform may be involved in starting and driving apoptogenesis in pyF111 fibroblasts exposed to topoisomerase-II inhibitors.
Subject(s)
Cell Transformation, Viral , Fibroblasts/enzymology , Isoenzymes/metabolism , Nuclear Envelope/enzymology , Polyomavirus/physiology , Protein Kinase C/metabolism , Topoisomerase II Inhibitors , Animals , Caspases/physiology , Catalysis , Cell Division , Doxorubicin/pharmacology , Enzyme Inhibitors/pharmacology , Etoposide/pharmacology , Fibroblasts/ultrastructure , Fibroblasts/virology , Protein Kinase C-delta , Rats , Rats, Inbred F344 , Teniposide/pharmacologyABSTRACT
Trimers of bovine pancreatic RNase A were obtained by cross-linking native RNase A with dimethyl suberimidate. They degrade double-stranded RNA more efficiently than dimers and monomers of RNase A, and display significant cytotoxic and/or cytostatic actions against C4-I cells (a human cell line derived from squamous carcinoma of the uterus cervix). On the same cell line cross-linked dimers of RNase A appear to be ineffective.
Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , RNA, Double-Stranded/metabolism , Ribonuclease, Pancreatic/chemistry , Ribonuclease, Pancreatic/metabolism , Animals , Antineoplastic Agents/metabolism , Cattle , Cell Survival/drug effects , Chromatography, Gel , Cross-Linking Reagents , Dimerization , Dimethyl Suberimidate , Humans , Nucleic Acid Conformation , Pancreas/enzymology , Protein Conformation , Ribonuclease, Pancreatic/pharmacology , Tumor Cells, CulturedABSTRACT
In order to establish what role members of the activating protein-1 (AP-1) gene families, i.e., c-fos, c-jun, junB, and junD, play in thymic apoptosis, we have analyzed changes in their expression in response to three different agents: a glucocorticoid analog dexamethasone, an inhibitor of topoisomerase II teniposide VM26, and gamma radiation. All three agents induced thymic death at a similar rate and with the same morphological and biochemical features. There was a rapid and transient increase in the steady-state mRNA level of junB and c-fos genes in all treatments, including control cultures, reminiscent rather of cellular stress response to the environmental changes than to the apoptotic stimuli. On the other hand, treatments with the DNA-damaging agents, VM26 and gamma radiation, resulted in superinduction of the c-jun mRNA and in the activation of the stress response signaling pathway of c-Jun N-terminal kinase. Gene transcription ceased completely in cells with fragmented DNA and the down-regulation of genes such as junD and tubulin was reflective of the thymocytes' commitment to apoptosis. The DNA-binding activities of the serum response factors, cyclic AMP response element binding proteins, and AP-1 factors, indicative of their transcriptional competence, were compromised shortly after induction of apoptosis regardless of the agent employed, consistent with previously reported enhancement in cellular proteolysis which is an essential component of the apoptotic cell death.
Subject(s)
Dexamethasone/pharmacology , Gamma Rays , Glucocorticoids/pharmacology , JNK Mitogen-Activated Protein Kinases , Mitogen-Activated Protein Kinase Kinases , Protein Kinases/metabolism , Proto-Oncogene Proteins c-jun/metabolism , Teniposide/pharmacology , Thymus Gland/enzymology , Topoisomerase II Inhibitors , Animals , Apoptosis/physiology , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cells, Cultured , Enzyme Activation , Gene Expression/drug effects , Gene Expression/radiation effects , Humans , MAP Kinase Kinase 4 , Male , Mice , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-jun/genetics , Rats , Rats, Sprague-Dawley , Thymus Gland/cytology , Thymus Gland/drug effects , Transcription Factor AP-1/metabolismABSTRACT
The intricate modulatory roles played by manifold hormones, growth factors, cytokines, extracellular calcium concentrations, intracellular second messengers, protein kinases, and nuclear poly(ADP-ribose) polymerase in proliferative, differentiative, and apoptotic processes have been the subject of investigations that were carried out by means of in vitro either primary or secondary/tertiary cultures of differentiated epithelial (hepatocytes, keratinocytes, and adrenocytes) and connective tissue cells (osteoblasts and fibroblasts) obtained from man and/or other mammalians. In most cases, an ad hoc model system, in which cells were floated on the top of the growth medium and, hence, could enjoy nearly normal respiratory exchanges, was used. Such a system increased cell viability and the ability of parenchymal epithelial cells to respond to extremely low concentrations of growth factors, hormones, and pharmaco-toxicological agents in a way conceivably very close to their behaviour in vivo.
Subject(s)
Adrenal Cortex/cytology , Apoptosis/physiology , Bone and Bones/cytology , Cell Differentiation/physiology , Cell Division/physiology , Liver/cytology , Skin/cytology , Adrenal Cortex/drug effects , Adrenocorticotropic Hormone/pharmacology , Adrenocorticotropic Hormone/physiology , Animals , Animals, Newborn , Apoptosis/drug effects , Arachidonic Acid/physiology , Bone Morphogenetic Proteins/pharmacology , Bone and Bones/drug effects , Calcium/physiology , Carcinogens/pharmacology , Carcinogens/toxicity , Cell Differentiation/drug effects , Cell Division/drug effects , Cells, Cultured , Cyclic AMP/physiology , Epidermal Growth Factor/physiology , Fibroblasts/cytology , Fibroblasts/drug effects , Gene Expression , Glucagon/physiology , Humans , Insulin/physiology , Keratinocytes/cytology , Keratinocytes/drug effects , Liver/drug effects , Liver Neoplasms, Experimental/etiology , Liver Neoplasms, Experimental/metabolism , Mammals , Osteoblasts/cytology , Osteoblasts/drug effects , Prostaglandins/physiology , Rats , Skin/drug effects , Transforming Growth Factor alpha/physiologyABSTRACT
The adequate management of burns is the requisite to save the patient's life, to prevent the onset of secondary infections and to obtain healing with acceptable cosmetic results. Previous data have shown that the use of alloskin grafts in the acute phase of burns yields the best clinical results. Unfortunately, this approach is curbed by the patient's immune response which induces the rejection of the allografts. In this report we endeavoured to solve this problem by ways that would not imply the general suppression of the patient's immune system. Thus, we can now report that a longer survival of alloskin grafts can be induced in situ by pretreating the alloskin samples to be grafted with both an anti-beta 2-microglobulin monoclonal antibody (beta 2mAb) and irradiation with ultraviolet-C light (UVC). The advantage of our novel approach is that it does not need any concomitant administration of immunosuppressive agent(s) to the burned patients. In this study, we followed five severely burned patients grafted with alloskin samples pretreated with either beta 2mAb or beta 2mAb plus UVC irradiation. In comparison with untreated alloskin samples from the same source grafted in parallel, the mean survival time (MST) of the beta 2mAb-pretreated alloskin specimens increased by 35 per cent (i.e. from 18.3 +/- 3.2 days to 24.7 +/- 5.5 days) in three patients. Moreover, the MST of the alloskin grafts pretreated with both beta 2mAb and UVC irradiation was lengthened by 100 per cent (i.e. from 18.5 +/- 4.5 days to 37.0 +/- 8.0 days) in the remaining two patients. These preliminary results lend credence to the view that local immune suppression could be achieved in situ by our approach via: (1) the impairment of the proper functions of the HLA-class I antigen by the bound beta 2mAb; and (2) the inhibition of immune reactions taking place inside the alloskin grafts by some immunosuppressive signal(s) generated by the UVC-pretreated alloepidermal cells. Hence, our approach stands as an exciting and useful alternative to the otherwise well-known, deleterious general suppression of the burned patient's immune system.
Subject(s)
Burns , Graft Enhancement, Immunologic , Skin Transplantation/immunology , Adolescent , Aged , Burns/immunology , Burns/surgery , Child , Female , Graft Survival , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Sampling Studies , Skin Transplantation/methods , Transplantation, Homologous , Wound Healing/physiologyABSTRACT
12-O-Tetradecanoylphorbol 13-acetate (TPA) elicited a transient increase in the transcription of the inducible nitric oxide synthase (iNOS) gene coupled with a shortening of the half-life of its mRNA in primary neonatal rat hepatocytes. These effects of TPA were preceded by a surge in nuclear translocation of the transcription factor NF-kappa B, and followed by a mounting accumulation of NO-2 in the growth medium. Even cycloheximide (CHX) added by itself elicited an early, sustained activation of NF-kappa B followed by an intense induction of iNOS gene expression, irrespective of what degree of protein synthesis inhibition was brought about by the several concentrations tested. When given together, TPA and CHX exerted additive effects on hepatocellular iNOS mRNA levels. These results suggest the likelihood of an ordered sequence of events by which an activated NF-kappa B mediates the induction of iNOS gene expression in TPA- and/or CHX-treated primary hepatocytes.
Subject(s)
Cycloheximide/pharmacology , Liver/metabolism , NF-kappa B/genetics , Nitric Oxide Synthase/genetics , Tetradecanoylphorbol Acetate/pharmacology , Animals , Base Sequence , Gene Expression Regulation/drug effects , Liver/cytology , Liver/drug effects , Molecular Sequence Data , NF-kappa B/metabolism , Nitric Oxide Synthase/metabolism , Rats , Rats, Wistar , Transcription, GeneticABSTRACT
Low concentrations of the C-terminal parathyroid hormone-related protein (PTHrP) fragments, PTHrP-(107-111) and PTHrP-(107-139), stimulated membrane-associated protein kinase Cs (PKCs), but not adenylyl cyclase or an internal Ca2+ surge, in early passage human skin keratinocytes and BALB/MK-2 murine skin keratinocytes. The fragment maximally stimulated membrane-associated PKCs in BALB/MK-2 cells at 5 x 10(-9) to 10(-8) M. The maximally PKC-stimulating concentrations of PTHrP-(107-111) also stopped or stimulated BALB/MK-2 keratinocyte proliferation depending on whether the cells were, respectively, cycling or quiescent at the time of exposure. Thus, just one brief (30-minute) pulse of 10(-8) M PTHrP-(107-111) stopped the proliferation of BALB/MK-2 keratinocytes for at least 5 days. On the other hand, daily 30-minute pulses of 10(-8) M PTHrP-(107-111) started and then maintained the proliferation of initially quiescent BALB/MK-2 cells. Similarly PTHrP-(107-111) inhibited DNA synthesis by cycling primary adult human keratinocytes, but it stimulated DNA synthesis by quiescent human keratinocytes.
Subject(s)
Keratinocytes/enzymology , Parathyroid Hormone-Related Protein , Parathyroid Hormone/physiology , Peptide Fragments/physiology , Protein Kinase C/metabolism , Proteins/physiology , Adenylyl Cyclases/metabolism , Adult , Amino Acid Sequence , Animals , Calcium/metabolism , Cell Cycle/physiology , Cell Division/physiology , Cells, Cultured/cytology , Cells, Cultured/enzymology , Culture Media , Epidermal Cells , Humans , Keratinocytes/cytology , Membrane Proteins/physiology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Phosphorylation , Temperature , Thymidine/metabolism , Time Factors , TritiumABSTRACT
The dermis is an important element in skin substitutes and in allo- or xeno-skin grafts. However, the reason(s) why dermis does not significantly induce the immune rejection reaction in vivo remain(s) hitherto unknown. To clarify the mechanisms underlying this phenomenon, we undertook the evaluation of: (i) the response of the peripheral blood mononuclear cells (PBM) to isolated allo-dermal cells or to pieces of or to whole allo-dermis, (ii) the migration and homing of the PBM inside allo-dermis or split thickness allo-skin, (iii) the distribution of the ICAM-1 protein within skin, and (iv) the features expressed by the PBM that migrate into allo-skin. The results herein presented show that (1) the isolated allo-dermal cells had the highest and the whole allo-dermis the lowest capacity to initiate the reactive proliferation of the PBM in vitro; (2) in an allo-skin/PBM co-culture model, most of the PBM slowly, yet preferentially, migrated to and homed inside the allo-epidermal compartment, instead of staying in the allo-dermis; (3) under the conditions employed, rather little ICAM-1 could be immunohistochemically detected within the epidermis, conversely, both the dermal cells and the dermal matrix were ICAM-1 positive; and (4) most of the PBM migrating into the allo-skin pieces expressed either the CD18 or the CD19 or the CD8 molecule, yet very few of them exhibited the LFA-1-antigen, and none of them were found to be CD4 positive.2+Therefore, we conclude that because
Subject(s)
Chemotaxis, Leukocyte/immunology , Epidermis/immunology , Graft Rejection/immunology , Leukocytes, Mononuclear/immunology , Skin Transplantation/immunology , Skin Transplantation/pathology , Cell Adhesion/immunology , Cell Adhesion Molecules/physiology , Cell Division/immunology , Cell Movement/immunology , Culture Techniques , Epidermal Cells , Humans , Intercellular Adhesion Molecule-1/physiology , Leukocytes, Mononuclear/cytology , Lymphocyte Function-Associated Antigen-1/physiology , Transplantation, HomologousABSTRACT
Shreds of biopsied adult human jaw bones were divided into four groups that were each incubated together with borosilicate glass chips in one of four variants of DMEM expansion medium (i.e., with a high or low calcium complement and with or without sodium ascorbate added). The outgrown bone cells were propagated in secondary cultures kept in the same DMEM expansion medium variants prior to being transferred to a beta-glycerophosphate-enriched high-Ca2+ and ascorbate-containing DMEM mineralisation medium. In this latter medium the proliferation rates and the simultaneous expression of alkaline phosphatase by the four distinct groups of osteoblasts were assessed during 7 days of staying in vitro via biochemical methods. Human osteoblasts previously expanded in high-Ca2+ ascorbate-added DMEM medium were found to initially express a quite high alkaline phosphatase activity that subsequently declined, while their proliferative activity remained rather low. Conversely, osteoblasts formerly expanded in low-Ca2+ ascorbate-devoid DMEM medium exhibited minimal levels of alkaline phosphatase activity while simultaneously maximally proliferating in the mineralisation medium. Moreover, a mixture (1:1 v/v) of the DMEM mineralisation medium with Ham's medium (in which the aminoacid proline abounds) was found to accelerate, in comparison to DMEM alone, the intracellular type I procollagen synthesis, the extracellular assembly of type I collagen fibrils, and the calcification of the extracellular matrix by the human osteoblasts. Hence, the presence or absence of calcium and/or ascorbate in the expansion medium and of proline in mineralisation medium can significantly modulate the progression of human jaw bone cells from an undifferentiated highly proliferating condition to the mature osteoblastic phenotype.
Subject(s)
Cell Culture Techniques/methods , Jaw/embryology , Jaw/metabolism , Maxillofacial Development/physiology , Osteoblasts/cytology , Osteoblasts/metabolism , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/metabolism , Ascorbic Acid/metabolism , Calcification, Physiologic/drug effects , Calcification, Physiologic/physiology , Calcium/metabolism , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Division/drug effects , Cell Division/physiology , Cells, Cultured/cytology , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Culture Media , DNA/biosynthesis , DNA/drug effects , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Humans , Jaw/drug effects , Maxillofacial Development/drug effects , Osteoblasts/drug effects , PhenotypeABSTRACT
Many of the known roles of arginine (e.g. in immune function, wound healing, and protection against ammonia intoxication) are mediated by a metabolic pathway synthesising nitric oxide (NO) in the liver. Contrary to some of the current views, liver-produced NO may be basically beneficial, as it exerts both protective actions against tissue injury and cytotoxic effects on invading microorganisms, parasites, or tumor cells. An ongoing equilibrium between NO and other NO-reactive compounds (e.g. O2 and non-heme iron-sulphur-containing moieties) appears to be important in this respect, even under critical conditions. Thus, NO may prevent liver tissue harm from oxidant stress. Only when this putative counterbalance is upset by an uncontrolled, prolonged and/or massive production of NO, liver tissue damage may occur leading to hepatic inflammation or even tumor development. Moreover, the currently available data support the working hypothesis that hepatocytes partake not only to immunoregulatory processes, but even to immune defence mechanisms. Thus, the liver constitutes an excellent model for investigations into the crosstalks regulating the production of NO which take place among not only the various networks operating inside a single hepatic cell, but even the individual types of liver cells.
Subject(s)
Apoptosis/physiology , Nitric Oxide/physiology , Animals , Apoptosis/drug effects , Brain/metabolism , DNA Damage , Endothelium, Vascular/metabolism , Enzyme Induction/drug effects , Enzyme Inhibitors/pharmacology , Free Radicals , Genes, p53 , Glutamic Acid/toxicity , Macrophages/drug effects , Macrophages/metabolism , Mice , Necrosis , Neurons/drug effects , Neurons/metabolism , Nitric Oxide/toxicity , Nitric Oxide Synthase/metabolism , Pancreas/drug effects , Pancreas/metabolism , Receptors, N-Methyl-D-Aspartate/drug effects , Signal Transduction/physiologyABSTRACT
Dexamethasone (Dex) accelerates the rate of apoptosis in thymocytes by a process thought to require gene expression. Among the genes implicated in the regulation of this phenomenon are the immediate early genes such as c-fos and c-jun, whose expression is modulated by a complement of preexisting transcription factors. We have analyzed the DNA-binding activity of these constitutive transcription factors during Dex-induced apoptosis in thymocytes to assess their functionality. We observed a progressive loss of the DNA-binding proteins in parallel with the appearance of the characteristic morphological and biochemical features of apoptosis. At the same time we have found a general increase in the nuclear proteolytic activity concomitant with a significant loss of the nuclear nonhistone chromosomal proteins. Indeed, cotreatment of thymocytes with the nonspecific serine protease inhibitor phenylmethylsulphonyl fluoride was able to partially protect the stability of the DNA-binding proteins and alter the expression of the c-fos and c-jun genes but did not inhibit apoptosis. Our results suggest that the action of a protease(s) is responsible for the degradation of constitutive transcription factors during Dex-induced apoptosis, rendering the death pathway irreversible.
Subject(s)
Apoptosis , Cyclic AMP Response Element-Binding Protein/metabolism , Thymus Gland/metabolism , Transcription Factor AP-1/metabolism , Animals , Apoptosis/drug effects , Apoptosis/genetics , Base Sequence , Cells, Cultured , DNA, Complementary , Dexamethasone/pharmacology , Gene Expression , Genes, fos , Genes, jun , Male , Molecular Sequence Data , Rats , Rats, Sprague-Dawley , Thymus Gland/drug effects , Thymus Gland/pathologyABSTRACT
The cells in nearly pure (96-98%) primary cultures of hepatocytes from neonatal rat liver in high (1.0 mM)-Ca2+, serum-free, synthetic HiWo5Ba2000 medium initiated DNA synthesis and entered mitosis between 11 and 30 h after the addition of 10 ng/ml EGF. During the 10-h prereplicative period, the cultured hepatocytes, like regenerating rat liver cells, generated two large cyclic AMP transients, one peaking between 30 min and 2 h and the other around 6 h. Hepatocytes stimulated by the same concentration of EGF in low (0.02 mM)-Ca2+ medium increased cyclic AMP synthesis as much as the EGF-treated hepatocytes in high-Ca2+ medium, but they released the additional cyclic AMP into the medium and could not generate prereplicative internal cyclic AMP surges, initiate DNA replication, or enter mitosis. These results suggest that one of the ways external Ca2+ controls prereplicative development of hepatocytes is to restrain the release of cyclic AMP and thus enable the cell to accumulate enough internal cyclic AMP to stimulate events required to initiate DNA replication.
Subject(s)
Calcium/metabolism , Cyclic AMP/metabolism , Epidermal Growth Factor/pharmacology , Extracellular Space/metabolism , Liver/drug effects , Liver/metabolism , Animals , Animals, Newborn , Cell Division/drug effects , Cells, Cultured , Culture Media/metabolism , Liver/cytology , Rats , Rats, WistarABSTRACT
Five murine hepatocellular tumor cell lines (HepM-1-5) were isolated and grown in a synthetic medium added with hormones, growth factors and/or serum. The morphology of these lines ranged from a nearly homogeneous epithelial-like shape (HepM-2) to a stromal appearance (HepM-1). The remaining lines displayed a mixed morphology. For their proliferation all of the cell lines retained a clear dependence on the extracellular calcium level and hormonal and/or serum growth factors and, rather homogeneously, they did not express the albumin, alpha-fetoprotein (with the exception of HepM-2 cells), tyrosine aminotransferase, and ornithine transcarbamylase genes, whereas they all exhibited discrete levels of the ornithine aminotransferase mRNA. Only HepM-3 and HepM-5 lines expressed the procollagen type I gene.
Subject(s)
Gene Expression Regulation, Neoplastic , Liver Neoplasms, Experimental/physiopathology , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Animals , Cell Division , Collagen/genetics , In Vitro Techniques , Liver/physiology , Male , Mice , Mice, Inbred A , Ornithine Carbamoyltransferase/genetics , Ornithine-Oxo-Acid Transaminase/genetics , Serum Albumin/genetics , Tumor Cells, Cultured , Tyrosine Transaminase/genetics , alpha-Fetoproteins/geneticsABSTRACT
Antigen-presenting cells (APC) play important roles in the allo-reactive proliferation of T cells in vitro and in the allo-graft rejection in vivo. This work was aimed at establishing whether a co-operation of any kind occurs between donor's and recipient's APC during allo-reactions, and whether certain cell surface molecules, such as beta 2-microglobulin (beta 2m) and human leucocyte antigens (HLA), are involved in such an interaction. The data herein reported show that the allo-reactive proliferation of peripheral blood lymphocytes (PBL) is markedly intensified by a positive co-operation between donor's and recipient's APC. Such a synergistic co-stimulatory action can be significantly hindered by a monoclonal antibody aimed against beta 2m while being not changed by monoclonal antibodies binding to either HLA-A-B-C or HLA-DR molecules. Hence, our preliminary results indicate that a positive interaction between donor's and recipient's APC may be of importance for allo-graft rejection.
Subject(s)
Antigen-Presenting Cells/immunology , Lymphocyte Activation , Lymphocytes/immunology , Cells, Cultured , DNA/biosynthesis , Graft Rejection , HLA Antigens/immunology , Humans , Lymphocyte Culture Test, Mixed , Transplantation, Homologous , beta 2-Microglobulin/immunologyABSTRACT
The feasibility of using antigenically disguised skin xenotransplants to cover extensive burns for a suitable time lag without administering immunosuppressive drugs was tested experimentally. Pieces of human skin that had been preincubated for 3 h at 37 degrees C with either mouse anti-human beta 2-microglobulin monoclonal antibody (beta 2m-McAb) or PBS (controls) were grafted onto the backs of immunologically competent Swiss mice, and the time required for their rejection or substitution by normal autogenous skin was determined. Thus, it was found that the beta 2m-McAb-pretreated xenografts had a significantly longer mean survival time than the control grafts. An even longer skin xenograft MST was obtained when beta 2m-McAb was repeatedly injected, at weekly intervals, just beneath the transplants. Parallel immunohistochemical studies showed that the beta 2m-McAb entered the grafts and was bound to its targets both in epidermis and dermis. Moreover, a small amount of beta 2m-McAb administered at the outset significantly hindered the reactive proliferation of primed mouse spleen cells cultured in the presence of human epidermal cells. Finally, neither toxic effects nor a weakening of immune competence were elicited by repeated intraperitoneal injections of beta 2m-McAb. Therefore, it seems expedient to propose the use of beta 2m-McAb to delay the rejection of skin xenografts as this antibody harmlessly prevents, wholly or in part, the activation of the recipients' lymphocytes. This would positively aid any patient urgently needing xenograft cover of extensive burns.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Graft Survival , Skin Transplantation , Transplantation, Heterologous , beta 2-Microglobulin/immunology , Animals , Antibodies, Monoclonal/toxicity , Female , Humans , Lymphocyte Culture Test, Mixed , Mice , Mice, Inbred Strains , Skin/cytology , Skin/immunology , Transplantation ImmunologyABSTRACT
Studies on cultured human renin(R)-producing tumors cells are few. In this work the R secretion by a human juxtaglomerular tumor (JGT) in various tissue culture models was evaluated by a new immunoradiometric assay. Freshly isolated JGT cells actively secreted total R (tR; about 70% of which is proR) into the perfusion media of very short-term cultures (tR concentration, 100-400 ng/ml/10(6) cells), independently of factors stimulating or inhibiting R output by normal JG cells. Primary monolayer cultures of the same JGT rapidly lost their tR-secreting capability and died by apoptosis within two months. Conversely, a JGT explant survived for up to 22 months in vitro. During the first year of culture, this explant increased in volume and generated, at 3- to 4-monthly intervals, several self-limited cellular outgrowths, from which it became detached. Meanwhile, tR secretion by the explant decreased very slowly, though its decline was transiently and partly reversed by various combinations of growth factors, hormones, a prostaglandin, and selenous acid added to either a serum-enriched or a synthetic medium. By the 12th month in vitro, tR secretion had faded away. Like the primary monolayers, the various explant outgrowths, once detached, stopped secreting tR and died in a few weeks. Hence, the preservation of a histiotypic relationship and the actions of several mitogenic and/or differentiating agents are essential for the long-term survival and the continuance of R secretion by human JGT cells in vitro.